Latest On Kaleido Biosciences, Inc (KLDO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-04-08 17:02 EST | News | Kaleido Biosciences to delist from Nasdaq as business operations end | N/A |  |
| 2022-01-31 03:10 EST | News | Kaleido Bio discontinues Phase 2 KB109 study, ends collaboration with COPD Foundation | N/A | |
| 2021-12-08 08:28 EST | News | Kaleido Biosciences (KLDO) Investor Presentation - Slideshow | N/A | |
| 2021-11-10 10:35 EST | News | Kaleido Biosciences picked industry veteran as chief medical officer | N/A | |
| 2021-11-01 22:03 EST | News | Kaleido Biosciences EPS misses by $0.02, misses on revenue | N/A | |
About Kaleido Biosciences, Inc (KLDO):
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
General
- Name Kaleido Biosciences, Inc
- Symbol KLDO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 82
- Fiscal Year EndDecember
- IPO Date2019-02-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://kaleido.com
Valuation
- Price/Sales (Trailing 12 Mt.) 344.11
- Price/Book (Most Recent Quarter) 20.78
- Enterprise Value Revenue 425.81
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.39
- Next Year EPS Estimate -$2.18
- Next Quarter EPS Estimate -$0.48
- Operating Margin -8090%
- Return on Assets -70%
- Return on Equity -235%
- Revenue 975000
- Earnings Per Share -$6.24
- Revenue Per Share $0.03
- Gross Profit -54992000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 438.26 million
- EBITDA -82607000
- Analyst Target Price $15.57
- Book Value Per Share $0.57
Share Statistics
- Shares Outstanding 42.47 million
- Shares Float 20.72 million
- % Held by Insiders 503%
- % Held by Institutions 79.77%
- Shares Short 2.6 million
- Shares Short Prior Month 2.76 million
- Short Ratio 5.92
- Short % of Float 12%
- Short % of Shares Outstanding 6%
Technicals
- Beta -0.27
- 52 Week High $16.93
- 52 Week Low $4.55
- 50 Day Moving Average 10.96
- 200 Day Moving Average 9.1
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Kaleido Biosciences, Inc (KLDO) Dividend Calendar:
Kaleido Biosciences, Inc (KLDO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Kaleido Biosciences, Inc (KLDO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Kaleido Biosciences, Inc (KLDO) Chart:
Kaleido Biosciences, Inc (KLDO) News:
Below you will find a list of latest news for Kaleido Biosciences, Inc (KLDO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Kaleido Biosciences, Inc (KLDO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Kaleido Biosciences, Inc (KLDO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-02 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-10-19 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-13 | 8-K (Current report) | |
| 2020-10-01 | 8-K (Current report) | |
| 2020-08-14 | EFFECT (Notice of Effectiveness) | |
| 2020-08-12 | UPLOAD (SEC-generated letter) | |
| 2020-08-12 | CORRESP (Correspondence) | |
| 2020-08-04 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-04 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-04 | 8-K (Current report) | |
| 2020-07-23 | 8-K (Current report) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-01 | 4 (Statement of changes in beneficial ownership of securities) | |
Kaleido Biosciences, Inc (KLDO) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kaleido Biosciences, Inc (KLDO). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 503%
Institutional Ownership: 7977%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-04 | Flagship Ventures Fund IV General Partner LLC | 10% Share Holder | Buy | 666,667.00 | 7.50 | 5,000,002.50 | 1,613,778.00 | |
| 2020-06-04 | Flagship Ventures Fund IV General Partner LLC | 10% Share Holder | Buy | 666,667.00 | 7.50 | 5,000,002.50 | 2,910,972.00 | |
| 2020-06-04 | KYRIAZI THEO MELAS | Director | Buy | 33,333.00 | 7.50 | 249,997.50 | 33,333.00 | |
| 2020-06-04 | Flagship Ventures Fund IV General Partner LLC | 10% Share Holder | Buy | 666,666.00 | 7.50 | 4,999,995.00 | 666,666.00 | |
| 2019-03-04 | Flagship Ventures Fund V General Partner LLC | Director | Buy | 333,333.00 | 15.00 | 4,999,995.00 | 2,244,305.00 | |
| 2019-03-04 | Flagship Ventures Fund V General Partner LLC | Director | Buy | 266,667.00 | 15.00 | 4,000,005.00 | 2,560,096.00 | |
| 2019-03-04 | Flagship Ventures Fund V General Partner LLC | Director | Buy | 333,333.00 | 15.00 | 4,999,995.00 | 6,560,523.00 | |
| 2019-02-28 | MICHAEL W BONNEY | Executive Chair | Buy | 68,965.00 | 13.95 | 962,061.75 | 1,005,968.00 | |
| 2019-02-28 | MICHAEL W BONNEY | Executive Chair | Buy | 2,555.00 | 14.65 | 37,430.75 | 1,008,523.00 | |